Kala reported US$6.1 million in full year 2019 revenue in its financial results for the fourth quarter and full year ended December 31, 2019.
Kala Pharmaceuticals (NASDAQ:KALA) reported US$6.1 million in full year 2019 revenue in its financial results for the fourth quarter and full year ended December 31, 2019.
As quoted in the press release:
“The last patient has now completed their final study visit in the STRIDE 3 Phase 3 trial,” said Mark Iwicki, Chief Executive Officer of Kala. “We are on track to report topline data in this quarter and to resubmit our New Drug Application to the U.S. Food and Drug Administration in the second quarter of 2020. If approved, we believe that EYSUVIS (KPI-121 0.25%), our product candidate for dry eye disease, could become the preferred prescription therapy for dry eye flares, which affects the vast majority of patients with dry eye disease. In 2019, we successfully launched INVELTYS, achieving steady growth in prescriptions and market share, and we continue to build a broad base of prescribing eye care professionals. This reflects the strong demand we are seeing for INVELTYS in the marketplace, as well as the execution of our commercial team. Our field sales, marketing and market access infrastructure has us well-positioned to rapidly launch EYSUVIS later this year, if approved.”